Development and validation of a predictive model for endoscopic improvement of Crohn's disease

Table 1 General characteristics of the training group

Item	Endoscopic improvement		P value
	Yes (n = 87)	No (n = 83)
Sex			0.199
Man	72	62
Woman	15	21
Age (years)	26 (20-32)	29 (23-34)	0.042
BMI (kg/m2)	19.03 (17.57-20.98)	19.31 (17.92-21.26)	0.843
Disease course (months)	6 (2-12)	11 (3-24)	0.051
Interval (months)	5 (4-8)	7 (4-13)	0.029
Clinical improvement			0.0091
Yes	85	72
No	2	11
First diagnosis			0.384
Yes	63	55
No	24	28
Smoking			0.5361
Yes	7	4
No	80	79
Drinking			0.4881
Yes	0	1
No	87	82
History of gastrointestinal surgery			0.162
Yes	41	48
No	46	35
Perianal lesions			0.126
Yes	51	36
No	27	32
Age (A; years)			0.027
< 17 (A1)	0	0
17-40 (A2)	81	68
> 40 (A3)	6	15
CD location (L)			0.839
Terminal ileum (L1)	8	9
Colon (L2)	27	28
Ileocolon (L3)	52	46
CD behavior (B)			0.4111
Inflammatory (B1)	69	60
Structuring (B2)	17	20
Penetrating (B3)	1	3
Medication			0.0941
Without medication	8	2
5-ASA	10	19
Corticosteroids	3	5
Immunosuppressants	5	6
Enteral nutrition	3	3
Biologics	71	50
Others	2	3
Changing amplitude of indicators (%)
BMI	2.86 (-2.38-15.04)	0.88 (-2.44-6.09)	0.173
ESR	-80.00 (-90.00 to -50.00)	-33.33 (-66.67-16.67)	< 0.001
Hb	9.57 (1.24-23.75)	3.08 (-2.72-10.69)	0.002
A/G	31.45 (15.03-55.77)	5.15 (-8.22-21.55)	< 0.001
ALB	11.49 (4.69-26.63)	1.29 (-4.50-10.30)	< 0.001
CRP	-93.54 (-98.59 to -52.73)	-49.65 (-85.56-13.37)	< 0.001
FIB	-36.24 ± 22.95	-8.98 ± 31.12	< 0.001

¹Fisher's exact test, and "others" refers to antibiotics, intestinal mucosal protectants, digestive drugs, etc.

BMI: Body mass index; CD: Crohn's disease; ASA: Aminosalicylic acid; ESR: Erythrocyte sedimentation rate; Hb: Hemoglobin; A/G: Albumin/globulin ratio; ALB: Albumin; CRP: C-reactive protein; FIB: Fibrinogen.